EP1996237B1 - Method for making polyethylene glycol carbonates - Google Patents
Method for making polyethylene glycol carbonates Download PDFInfo
- Publication number
- EP1996237B1 EP1996237B1 EP07751827A EP07751827A EP1996237B1 EP 1996237 B1 EP1996237 B1 EP 1996237B1 EP 07751827 A EP07751827 A EP 07751827A EP 07751827 A EP07751827 A EP 07751827A EP 1996237 B1 EP1996237 B1 EP 1996237B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polyalkylene glycol
- carbonate
- amine
- reagent
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/20—General preparatory processes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/20—General preparatory processes
- C08G64/30—General preparatory processes using carbonates
- C08G64/305—General preparatory processes using carbonates and alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/18—Block or graft polymers
- C08G64/186—Block or graft polymers containing polysiloxane sequences
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/20—General preparatory processes
- C08G64/26—General preparatory processes using halocarbonates
- C08G64/266—General preparatory processes using halocarbonates and alcohols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/42—Chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
Definitions
- This invention is in the field of methods for making polyethylene glycol carbonates.
- Biologically active compounds conjugated with polyoxyalkylenes can provide enhanced biocompatibility for the compound. See, for example, USP 5,366,735 and USP 6,280,745 .
- Polyethylene glycol (PEG) is a linear polyoxyalkylene terminated at the ends thereof with hydroxyl groups and generally represented by the formula: HO(CH 2 CH 2 O) n H.
- monomethyl polyethylene glycol (mPEG) generally represented by the formula: CH 3 O(CH 2 CH 2 O) n H, is often used to prepare a polyethylene glycol conjugate with a biologically active compound typically by way of a coupling reaction between the biologically active compound and a derivative of mPEG such as mPEG p-nitrophenyl carbonate.
- a biologically active compound coupled to PEG is said in the art to be "PEGylated”.
- a PEGylated biopharmaceutical agent increases as the molecular weight of the PEG chain is increased.
- One means of increasing the molecular weight of a PEG derivatizing agent is to form a "multi-armed" PEG derivative.
- a multi-armed PEG derivative comprises a plurality of PEG chains thereby increasing the molecular weight of the multi-armed PEG derivative.
- a multi-armed PEG derivative can be multi-functional (as discussed by Seely and Richey, by WO 97/32607 and by USPAP 2003/0065134 or mono-functional (as discussed by US Patents 5,919,455 and 5,932,462 .
- USP 5286637 The prior art methods for making mPEG carbonates, such as mPEG p-nitrophenyl carbonate, are set forth in USP 5286637 , by Fortier et al. Applied Biochemistry (1993) 17(1), 115-130 and by Veronese et al., Applied Biochem. Biotech. 11, 141-152 (1985 ).
- USP 5286637 is based on the reaction of mPEG with p-nitrophenyl chloroformate in a solvent of methylene chloride containing triethylamine.
- Fortier et al. used pyridine instead of triethylamine.
- Veronese et al. used acetonitrile instead of methylene chloride.
- the instant invention is a method for making polyalkylene glycol carbonates, preferably polyethylene glycol carbonates, which produces less of the above-mentioned type of impurity. More specifically, the instant invention is a method comprising reacting a polyalkylene glycol (preferably PEG) comprising at least one hydroxyl group with a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine.
- a polyalkylene glycol preferably PEG
- a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine.
- this is a method for making a linear, preferably alkyl terminated) polyalkylene glycol carbonate (preferably an alkyl polyethylene glycol carbonate) comprising the step of reacting mono-alkyl polyalkylene glycol (preferably mono-alkyl PEG) with a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine.
- a linear, preferably alkyl terminated) polyalkylene glycol carbonate preferably an alkyl polyethylene glycol carbonate
- the instant invention is a method for making a multi-armed polyalkylene glycol carbonate (preferably multi-armed PEG carbonate) comprising the step of reacting a multi-armed polyalkylene glycol (preferably multi-armed PEG) having at least one hydroxyl group with a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine.
- the amine used in this invention has the formula R 3 N, wherein R is independently in each occurrence an organic group comprising two or more carbon atoms.
- R may be a hydrocarbon containing only carbon and hydrogen or alternatively may be a moiety containing heteroatoms.
- the groups R can comprise linear, branched, saturated or unsaturated cyclic or polycyclic structure.
- Ris an aliphatic or aromatic hydrocarbon with alkyls being most preferred.
- R preferably, comprises independently in each occurrence less than ten carbon atoms.
- a highly preferred amine is triperitylamine.
- the reagent may be any carbonate or chloroformate reagent which would react with the hydroxyl group on the polyalkylene glycol to form a carbonate group.
- a chloroformate is used.
- the chloroformate is preferably an aryl chloroformate, more preferably a phenyl chloroformate, and most preferably is p-nitrophenyl chloroformate.
- aromatic solvent means a solvent comprising unsaturated cyclic groups containing one or more rings.
- a highly preferred aromatic solvent is toluene.
- the polyalkylene glycol is "multi-armed".
- a multiarmed polyalkylene glycol has a common core and one or more hydroxyl groups on the end of a PAG chain or at a point or points other than at the end of the PAG chain provided that if the PAG is linear, the PAG chain has at least two hydroxyl groups.
- the polyalkylene glycol is a multi-armed polyethylene glycol carbonate which can be mono-functional (comprising one carbonate group) or polyfunctional (comprising more than one carbonate group).
- the mono-alkyl polyethylene glycol and the aromatic solvent can be mixed and dried by azeotropic distillation before adding the chloroformate and the amine.
- the reaction is conducted at a temperature in the range of from 25 to 75 degrees Celsius.
- the reaction is conducted at a temperature in the range of from 50 to 60 degrees Celsius and the chloroformate is p-nitrophenyl chloroformate.
- the mole ratio of chloroformate to polyalkylene glycol is preferably at least 5:1, more preferably at least 8:1 and preferably no more than 20:1, more preferably no more than 12:1.
- the mole ratio of the amine to mono-alkyl polyethylene glycol is preferably at least 2.5:1, more preferably at least 4:1 and preferably no more than 10:1, more preferably no more than 6:1.
- the amount of solvent used per kilogram of mono-alkyl polyethylene glycol is preferably at least 2 liters more preferably at least 4 liters, and preferably no more than 10 liters, more preferably no more than 6 liters.
- the polyalkylene glycol preferably has a number average molecular weight of at least about 500, more preferably at least about 1000, and most preferably at least about 5000.
- the number average molecular weight is preferably no greater than about 100,000, more preferably no greater than about 60,000.
- the linear alkyl polyalkylene glycol carbonate compositions of the instant invention are preferably characterized by low polydispersity and relatively high defined molecular weight each as determined by size exclusion chromatography.
- Low polydispersity means polydispersity of less than 1.1.
- the alkyl polyethylene glycol carbonate preferably has a number average molecular weight of at least about 500, more preferably at least about 1000, and most preferably at least about 5000.
- the number average molecular weight is preferably no greater than about 100,000, more preferably no greater than about 60,000.
- the specific molecular weight may be chosen to suit the particular biomedical application for which the composition is required, for example a molecular weight of 10,000, 20,000, 30,000 or 40,000.
- the polyalkylene glycol carbonate (for convenience, the preferred methylPEG carbonate or mPEG carbonate will be referred to throughout this process description section but should not be considered as limiting) is preferably isolated by cooling the mixture and adding an anti-solvent (such as an ether, egg. MTBE, or an alkane, e.g. hexane or heptane) to precipitate the product, filtering the precipitate, and washing it with fresh anti-solvent.
- the mPEG carbonate is then preferably purified by redissolving in a solvent (such as methanol or THF), adding an anti-solvent (such as isopropanol, and ether, e.g. MTBE, or an alkane, e.g.
- the mPEG carbonate can then be dried in a vacuum oven at 25 -35 degrees Celsius.
- the product is preferably analyzed by proton NMR and liquid chromatography under critical conditions.
- the reaction is cooled to 35 °C and methyl t-butyl ether (MTBE; 10 L; 10 mL per gram mPEG-OH) is added all at once with increased agitation (350 rpm).
- MTBE methyl t-butyl ether
- the resulting thick slurry is cooled to 0 °C and stirred 30 minutes before isolating the solid on a sintered glass funnel by vacuum filtration.
- the reaction flask is rinsed, with ice cold MTBE (2.0 L; 2 mL per gram mPEG-OH) and this rinse used to wash the isolated solid.
- the solid is left under aspirator vacuum until no additional filtrate is evident.
- the semi-dry solid is then transferred back to the 20 L reactor and methanol (MeOH; 2.2 L; 2.2 mL per gram mPEG-OH) is added, including a 100 mL MeOH rinse on the isolation funnel.
- methanol MeOH; 2.2 L; 2.2 mL per gram mPEG-OH
- the resulting mixture is stirred gently (200 rpm) while heating to 40 °C under an inert atmosphere until a homogeneous solution is obtained (NOTE: if the solution remains hazy, it is preferably filtered again).
- Isopropanol IPA; 13.8 L; 13.8 mL per gram mPEG-OH
- the resulting thick slurry is stirred for 60 minutes before isolating the solid on a sintered glass funnel by vacuum filtration.
- the reaction flask is rinsed with cold SPA (6.3 L; 6.3 mL per gram mPEG-OH) and this rinse is used to wash the isolated solid.
- the solid is left under aspirator vacuum until no additional filtrate is evident.
- the semi-dry solid is dissolved in MeOH and re-precipitated from MeOH/IPA as described above two additional times.
- the final wet-cake is dried under high vacuum at 40 °C for 48 hours to give approximately 850 g of product as a white to light yellow solid.
- the product is analyzed by high performance liquid chromatography under critical conditions and by proton NMR.
- the reaction is cooled to 35 °C and methyl t-butyl ether (MTBE; 7 L; 10 mL per gram mPEG-OH) is added all at once with increased agitation (350 rpm).
- MTBE methyl t-butyl ether
- the resulting thick slurry is cooled to 0 °C and stirred 30 minutes before isolating the solid on a sintered glass funnel by vacuum filtration.
- the reaction flask is rinsed with ice cold MTBE (1.4 L; 2 mL per gram mPEG-OH) and this rinse used to wash the isolated solid.
- the solid is left under aspirator vacuum until no additional filtrate is evident.
- the semi-dry solid is then transferred back to the 20 L reactor and methanol (MeOH; 1.4 L; 2.2 mL per gram mPEG-OH) is added, including a 100 mL MeOH rinse on the isolation funnel.
- methanol MeOH; 1.4 L; 2.2 mL per gram mPEG-OH
- the resulting mixture is stirred gently (200 rpm) while heating to 40 °C under an inert atmosphere until a homogeneous solution is obtained (NOTE: if the solution remains hazy, it is preferably filtered again).
- Isopropanol IPA; 9.6 L; 13.8 mL per gram mPEG-OH
- the resulting thick slurry is stirred for 60 minutes before isolating the solid on a sintered glass funnel by vacuum filtration.
- the reaction flask is rinsed with cold IPA (4.4 L; 6.3 mL per gram mPEG-OH) and this rinse is used to wash the isolated solid.
- the solid is left under aspirator vacuum until no additional filtrate is evident.
- the semi-dry solid is dissolved in MeOH and re-precipitated from MeOH/IPA as described above two additional times.
- the final wet-cake is dried under high vacuum at 40 °C for 48 hours to give approximately 666 grams of product as a white to light yellow solid.
- the product is analyzed by high performance liquid chromatography under critical conditions and by proton NMR.
- a high pressure liquid chromatograph instrument is equipped with an evaporative light scattering detector and a UV detector set at 270 nm.
- the column is a Zorbax 330 SB (4/6 x 150 mm, 5 micron pore size) and is kept at 29 degrees Celsius.
- the eluants are (A) 40/60 v/v acetonitrile water, and (B) 50/50 v/v acetonitrile/water.
- Suitable equipment to use includes Agilent 1100 Series Liquid Chromatograph: Quaternary Pump G1311A; Vacuum Degasser G1322A; Autosampler G1313A ALS; Column Thermostat G1313A COLCOM; Variable Wavelength Detector G1314A Alltech 2000 Evaporative Light Scattering Detector. Zorbax 300SB-C 18 4.6 x 150 mm, 5 micron column at 29 degrees Celsius 0.75 mL/min Eluant Flow Rate. 5 microliter Injection Volume. UV detection at 270 nanometers, peak width greater than 0.1 minute, response time 2 seconds, attenuation 1000 mAu.
- Evaporative Light Scattering Detector gas flow 3.0 mL/min N2, tube temp 110 °C, Gain 1, Impactor Off.
- Software Agilent LC Chemstation Revision A.09.01. Eluant: (A) 40/60 v/v acetonitrile/water; (B) 50/50 v/v acetonitrile/water.
- Critical condition is determined by combining eluents (A) and (B) in a ratio so that PEG diols with molecular weights of 6K and 36K have the same retention time.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Polyesters Or Polycarbonates (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polyethers (AREA)
Abstract
Description
- This invention is in the field of methods for making polyethylene glycol carbonates.
- Biologically active compounds conjugated with polyoxyalkylenes (such as polyethylene glycol) can provide enhanced biocompatibility for the compound. See, for example,
USP 5,366,735 andUSP 6,280,745 . A review of this subject by Zalipsky, in Bioconjugate Chem., 1995, 6, p150-165, identified polyethylene glycol as one of the best biocompatible polymers to conjugate with a biologically active compound (such as a drug, a protein, a peptide or an enzyme) to produce a conjugate having improved properties such as compatible solubility characteristics, reduced toxicity, improved surface compatibility, increased circulation time and reduced immunogenicity. - Polyethylene glycol (PEG) is a linear polyoxyalkylene terminated at the ends thereof with hydroxyl groups and generally represented by the formula: HO(CH2CH2O)nH. As discussed by Henmanson in Chapter 15 of Bioconjugate Techniques (1996), monomethyl polyethylene glycol (mPEG) generally represented by the formula: CH3O(CH2CH2O)nH, is often used to prepare a polyethylene glycol conjugate with a biologically active compound typically by way of a coupling reaction between the biologically active compound and a derivative of mPEG such as mPEG p-nitrophenyl carbonate. A biologically active compound coupled to PEG is said in the art to be "PEGylated".
- As discussed by Seely and Richey, J. of Chrom. A, 908 (2001) 235-241 the serum half-life of a PEGylated biopharmaceutical agent increases as the molecular weight of the PEG chain is increased. One means of increasing the molecular weight of a PEG derivatizing agent is to form a "multi-armed" PEG derivative. A multi-armed PEG derivative comprises a plurality of PEG chains thereby increasing the molecular weight of the multi-armed PEG derivative. A multi-armed PEG derivative can be multi-functional (as discussed by
and bySeely and Richey, by WO 97/32607 or mono-functional (as discussed byUSPAP 2003/0065134 US Patents 5,919,455 and5,932,462 . - The prior art methods for making mPEG carbonates, such as mPEG p-nitrophenyl carbonate, are set forth in
USP 5286637 , by Fortier et al. Applied Biochemistry (1993) 17(1), 115-130 and by Veronese et al., Applied Biochem. Biotech. 11, 141-152 (1985).USP 5286637 is based on the reaction of mPEG with p-nitrophenyl chloroformate in a solvent of methylene chloride containing triethylamine. Fortier et al. used pyridine instead of triethylamine. Veronese et al. used acetonitrile instead of methylene chloride. All of these prior art methods for making mPEG p-nitrophenyl carbonate also produce an impurity (believed to be the amine salt of the hydrolyzed mPEG p-nitrophenyl carbonate) when the concentration of the REPEG p-nitrophenyl carbonate is relatively high, which impurity is difficult to separate from the mPEG p-nitrophenyl carbonate. Thus, there remains a need for an improved method for making mPEG carbonates (such as mPEG p-nitrophenyl carbonate) at relatively high concentration, which method never-the-Iess produces less impurity. - The instant invention is a method for making polyalkylene glycol carbonates, preferably polyethylene glycol carbonates, which produces less of the above-mentioned type of impurity. More specifically, the instant invention is a method comprising reacting a polyalkylene glycol (preferably PEG) comprising at least one hydroxyl group with a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine. According to one preferred embodiment, this is a method for making a linear, preferably alkyl terminated) polyalkylene glycol carbonate (preferably an alkyl polyethylene glycol carbonate) comprising the step of reacting mono-alkyl polyalkylene glycol (preferably mono-alkyl PEG) with a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine. In a related embodiment, the instant invention is a method for making a multi-armed polyalkylene glycol carbonate (preferably multi-armed PEG carbonate) comprising the step of reacting a multi-armed polyalkylene glycol (preferably multi-armed PEG) having at least one hydroxyl group with a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine.
- Preferably, the amine used in this invention has the formula R3N, wherein R is independently in each occurrence an organic group comprising two or more carbon atoms. R may be a hydrocarbon containing only carbon and hydrogen or alternatively may be a moiety containing heteroatoms. The groups R can comprise linear, branched, saturated or unsaturated cyclic or polycyclic structure. Preferably, Ris an aliphatic or aromatic hydrocarbon with alkyls being most preferred. R, preferably, comprises independently in each occurrence less than ten carbon atoms. A highly preferred amine is triperitylamine.
- The reagent may be any carbonate or chloroformate reagent which would react with the hydroxyl group on the polyalkylene glycol to form a carbonate group. Preferably, a chloroformate is used. The chloroformate is preferably an aryl chloroformate, more preferably a phenyl chloroformate, and most preferably is p-nitrophenyl chloroformate.
- The term "aromatic solvent" means a solvent comprising unsaturated cyclic groups containing one or more rings. A highly preferred aromatic solvent is toluene.
- According to the preferred embodiment where the polyalkylene glycol is linear and alkyl terminated the compound may be represented by the formula:
- R1-(O-R2)-OH where R1 is a hydrocarbon group, preferably an alkyl group of more preferably at least 1 carbon atom and more preferably no more than 7 carbon atoms, more preferably still 1 or 2 carbon atoms and R2 is a hydrocarbon, preferably an alkylene group of more preferably at least 1 carbon atom and more preferably no more than 5 carbon atoms. R1 is most preferably methyl and R2 is most preferably ethylene.
- According to the alternate embodiment the polyalkylene glycol (PAG) is "multi-armed". As used herein a multiarmed polyalkylene glycol has a common core and one or more hydroxyl groups on the end of a PAG chain or at a point or points other than at the end of the PAG chain provided that if the PAG is linear, the PAG chain has at least two hydroxyl groups. Preferably the polyalkylene glycol is a multi-armed polyethylene glycol carbonate which can be mono-functional (comprising one carbonate group) or polyfunctional (comprising more than one carbonate group).
- Optionally, the mono-alkyl polyethylene glycol and the aromatic solvent can be mixed and dried by azeotropic distillation before adding the chloroformate and the amine. Preferably, the reaction is conducted at a temperature in the range of from 25 to 75 degrees Celsius. Most preferably, the reaction is conducted at a temperature in the range of from 50 to 60 degrees Celsius and the chloroformate is p-nitrophenyl chloroformate. The mole ratio of chloroformate to polyalkylene glycol is preferably at least 5:1, more preferably at least 8:1 and preferably no more than 20:1, more preferably no more than 12:1. The mole ratio of the amine to mono-alkyl polyethylene glycol is preferably at least 2.5:1, more preferably at least 4:1 and preferably no more than 10:1, more preferably no more than 6:1.. The amount of solvent used per kilogram of mono-alkyl polyethylene glycol is preferably at least 2 liters more preferably at least 4 liters, and preferably no more than 10 liters, more preferably no more than 6 liters.
- The polyalkylene glycol preferably has a number average molecular weight of at least about 500, more preferably at least about 1000, and most preferably at least about 5000. The number average molecular weight is preferably no greater than about 100,000, more preferably no greater than about 60,000.
- The linear alkyl polyalkylene glycol carbonate compositions of the instant invention are preferably characterized by low polydispersity and relatively high defined molecular weight each as determined by size exclusion chromatography. Low polydispersity means polydispersity of less than 1.1. The alkyl polyethylene glycol carbonate preferably has a number average molecular weight of at least about 500, more preferably at least about 1000, and most preferably at least about 5000. The number average molecular weight is preferably no greater than about 100,000, more preferably no greater than about 60,000. The specific molecular weight may be chosen to suit the particular biomedical application for which the composition is required, for example a molecular weight of 10,000, 20,000, 30,000 or 40,000.
- The polyalkylene glycol carbonate (for convenience, the preferred methylPEG carbonate or mPEG carbonate will be referred to throughout this process description section but should not be considered as limiting) is preferably isolated by cooling the mixture and adding an anti-solvent (such as an ether, egg. MTBE, or an alkane, e.g. hexane or heptane) to precipitate the product, filtering the precipitate, and washing it with fresh anti-solvent. The mPEG carbonate is then preferably purified by redissolving in a solvent (such as methanol or THF), adding an anti-solvent (such as isopropanol, and ether, e.g. MTBE, or an alkane, e.g. hexane or heptane) to precipitate the product, filtering the precipitate, and washing it with fresh anti-solvent. The mPEG carbonate can then be dried in a vacuum oven at 25 -35 degrees Celsius. The product is preferably analyzed by proton NMR and liquid chromatography under critical conditions.
- To a 20L straight-walled jacketed reactor with bottom drain and thermowell, equipped with an overhead stirrer, cold water condenser and nitrogen inlet, is charged one kilogram of 20,000 gram per mole average molecular weight mPEG having a polydispersity of less than 1.1 and six liters of toluene. The resulting solution stirred (250 rpm) while heating to 60 °C before adding 73 milliliters of tripentylamine and 101 grams ofp-Nitrophenylchloroformate. An immediate yellow color forms, but quickly dissipates. The reaction is allowed to stir at 60 °C under an inert atmosphere until HPLC analysis under critical conditions indicates an essentially complete reaction. After approximately 18-24 hours of heating, the reaction is cooled to 35 °C and methyl t-butyl ether (MTBE; 10 L; 10 mL per gram mPEG-OH) is added all at once with increased agitation (350 rpm). The resulting thick slurry is cooled to 0 °C and stirred 30 minutes before isolating the solid on a sintered glass funnel by vacuum filtration. The reaction flask is rinsed, with ice cold MTBE (2.0 L; 2 mL per gram mPEG-OH) and this rinse used to wash the isolated solid. The solid is left under aspirator vacuum until no additional filtrate is evident. The semi-dry solid is then transferred back to the 20 L reactor and methanol (MeOH; 2.2 L; 2.2 mL per gram mPEG-OH) is added, including a 100 mL MeOH rinse on the isolation funnel. The resulting mixture is stirred gently (200 rpm) while heating to 40 °C under an inert atmosphere until a homogeneous solution is obtained (NOTE: if the solution remains hazy, it is preferably filtered again). Isopropanol (IPA; 13.8 L; 13.8 mL per gram mPEG-OH) is added over 1 hour and the solids start to precipitate out of solution. The mixture is then cooled to 0 °C. The resulting thick slurry is stirred for 60 minutes before isolating the solid on a sintered glass funnel by vacuum filtration. The reaction flask is rinsed with cold SPA (6.3 L; 6.3 mL per gram mPEG-OH) and this rinse is used to wash the isolated solid. The solid is left under aspirator vacuum until no additional filtrate is evident. The semi-dry solid is dissolved in MeOH and re-precipitated from MeOH/IPA as described above two additional times. The final wet-cake is dried under high vacuum at 40 °C for 48 hours to give approximately 850 g of product as a white to light yellow solid. The product is analyzed by high performance liquid chromatography under critical conditions and by proton NMR.
- To a 20L straight-walled jacketed reactor with bottom drain and thermowell, equipped with an overhead stirrer, cold water condenser and nitrogen inlet, is charged 700 grams of 10,000 gram per mole average molecular weight mPEG having a polydispersity of less than 1.1 and four liters of toluene. The resulting solution stirred (250 rpm) while heating to 60 °C before adding 100 milliliters of tripentylamine and 140 grams ofp-Nitrophenylchloroformate. An immediate yellow color forms, but quickly dissipates. The reaction is allowed to stir at 60 °C under an inert atmosphere until HPLC analysis under critical conditions indicates an essentially complete reaction. After approximately 18-24 hours of heating, the reaction is cooled to 35 °C and methyl t-butyl ether (MTBE; 7 L; 10 mL per gram mPEG-OH) is added all at once with increased agitation (350 rpm). The resulting thick slurry is cooled to 0 °C and stirred 30 minutes before isolating the solid on a sintered glass funnel by vacuum filtration. The reaction flask is rinsed with ice cold MTBE (1.4 L; 2 mL per gram mPEG-OH) and this rinse used to wash the isolated solid. The solid is left under aspirator vacuum until no additional filtrate is evident. The semi-dry solid is then transferred back to the 20 L reactor and methanol (MeOH; 1.4 L; 2.2 mL per gram mPEG-OH) is added, including a 100 mL MeOH rinse on the isolation funnel. The resulting mixture is stirred gently (200 rpm) while heating to 40 °C under an inert atmosphere until a homogeneous solution is obtained (NOTE: if the solution remains hazy, it is preferably filtered again). Isopropanol (IPA; 9.6 L; 13.8 mL per gram mPEG-OH) is added over 1 hour and the solids start to precipitate out of solution. The mixture is then cooled to 0 °C. The resulting thick slurry is stirred for 60 minutes before isolating the solid on a sintered glass funnel by vacuum filtration. The reaction flask is rinsed with cold IPA (4.4 L; 6.3 mL per gram mPEG-OH) and this rinse is used to wash the isolated solid. The solid is left under aspirator vacuum until no additional filtrate is evident. The semi-dry solid is dissolved in MeOH and re-precipitated from MeOH/IPA as described above two additional times. The final wet-cake is dried under high vacuum at 40 °C for 48 hours to give approximately 666 grams of product as a white to light yellow solid. The product is analyzed by high performance liquid chromatography under critical conditions and by proton NMR.
- A high pressure liquid chromatograph instrument is equipped with an evaporative light scattering detector and a UV detector set at 270 nm. The column is a Zorbax 330 SB (4/6 x 150 mm, 5 micron pore size) and is kept at 29 degrees Celsius. The eluants are (A) 40/60 v/v acetonitrile water, and (B) 50/50 v/v acetonitrile/water.
Suitable equipment to use includes Agilent 1100 Series Liquid Chromatograph: Quaternary Pump G1311A; Vacuum Degasser G1322A; Autosampler G1313A ALS; Column Thermostat G1313A COLCOM; Variable Wavelength Detector G1314A Alltech 2000 Evaporative Light Scattering Detector.
Zorbax 300SB-C 18 4.6 x 150 mm, 5 micron column at 29 degrees Celsius
0.75 mL/min Eluant Flow Rate.
5 microliter Injection Volume.
UV detection at 270 nanometers, peak width greater than 0.1 minute, response time 2 seconds, attenuation 1000 mAu.
Evaporative Light Scattering Detector: gas flow 3.0 mL/min N2, tube temp 110 °C, Gain 1, Impactor Off.
Software: Agilent LC Chemstation Revision A.09.01.
Eluant: (A) 40/60 v/v acetonitrile/water; (B) 50/50 v/v acetonitrile/water. - Critical condition is determined by combining eluents (A) and (B) in a ratio so that PEG diols with molecular weights of 6K and 36K have the same retention time.
- Sample Preparation: Dry PEG samples are dissolved at 50 mg/l gram of eluent A.
Wet cakes of PEG in MTBE are dissolved at 80 mg/l gram of eluent A.
Wet cakes of PEG in IP A are dissolved at 150 mg/l gram of eluent A.
Claims (15)
- A method for making a polyalkylene glycol carbonate comprising the step of reacting a hydroxyl functional polyalkylene glycol and a reagent selected from carbonates and chloroformates in the presence of an aromatic solvent and an amine.
- The method of claim 1 where the polyalkylene glycol carbonate is linear and terminates in an alkyl group at one end and a carbonate at the other end.
- The method of claim 2 where the polyalkylene glycol is methyl polyethylene glycol.
- The method of claim 1 wherein the polyalkylene glycol carbonate is multi-armed.
- The method of claim 4 where the polyalkylene glycol is polyethylene glycol.
- The method of any one of claims 1-5 wherein the reagent is an aryl chloroformate.
- The method of claim 6 wherein the reagent is a phenyl chloroformate.
- The method of claim 7 where the reagent is p-nitrophenyl chloroformate.
- The method of any one of claims 1-8 wherein the amine has the formula R3N, wherein R is independently in each occurrence an organic group comprising two or more carbon atoms.
- The method of claim 9 where R is independently in each occurrence a hydrocarbon group.
- The method of claim 10 where R is an alkyl group.
- The method of any one of claims 1-10, wherein the reaction is conducted at a temperature in the range of from 25 to 75 degrees Celsius.
- The method of any one of the claims 1 to 12, wherein the mole ratio of p-nitrophenyl chloroformate to polyalkylene glycol is in the range of from 5:1 to 20:1;
and/or the mole ratio of the amine to polyalkylene glycol is in the range of from 2.5:1 to 10:1; and/or from 2 to 10 liters of aromatic solvent are used per kilogram of polyalkylene glycol. - The method of any one of claims 1-13, wherein the aromatic solvent is toluene, and the amine is tripentylamine.
- The method of any one of claims 1-14, wherein the mole ratio of the reagent to the polyalkylene glycol is in the range of from 8:1 to 12:1, the mole ratio of the amine to the polyalkylene glycol is in the range of from 4:1 to 6:1 and from 4 to 6 liters of toluene are used per kilogram of polyalkylene glycol.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77737406P | 2006-02-28 | 2006-02-28 | |
| PCT/US2007/005094 WO2007100829A2 (en) | 2006-02-28 | 2007-02-27 | Method for making polyethylene glycol carbonates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1996237A2 EP1996237A2 (en) | 2008-12-03 |
| EP1996237B1 true EP1996237B1 (en) | 2010-07-28 |
Family
ID=38456515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP07751827A Not-in-force EP1996237B1 (en) | 2006-02-28 | 2007-02-27 | Method for making polyethylene glycol carbonates |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7816484B2 (en) |
| EP (1) | EP1996237B1 (en) |
| JP (1) | JP2009528430A (en) |
| KR (1) | KR20090042755A (en) |
| CN (1) | CN101500614B (en) |
| AT (1) | ATE475433T1 (en) |
| CA (1) | CA2656693A1 (en) |
| DE (1) | DE602007008074D1 (en) |
| WO (1) | WO2007100829A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104271630B (en) * | 2012-05-31 | 2017-07-28 | 陶氏环球技术有限公司 | Epoxy Resins for Aqueous Dispersions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911926A (en) * | 1988-11-16 | 1990-03-27 | Mediventures Inc. | Method and composition for reducing postsurgical adhesions |
| US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5286637A (en) * | 1989-08-07 | 1994-02-15 | Debiopharm, S.A. | Biologically active drug polymer derivatives and method for preparing same |
| CN1034345C (en) * | 1989-09-29 | 1997-03-26 | 三井石油化学工业株式会社 | Lubricating oil composition |
| US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5889153A (en) * | 1994-05-20 | 1999-03-30 | Hisamitsu Pharmaceutical Co., Inc. | Protein or polypeptide, method for producing the same and intermediate compound therefor |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6280745B1 (en) * | 1997-12-23 | 2001-08-28 | Alliance Pharmaceutical Corp. | Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions |
| US5747639A (en) | 1996-03-06 | 1998-05-05 | Amgen Boulder Inc. | Use of hydrophobic interaction chromatography to purify polyethylene glycols |
| US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| JP4123856B2 (en) * | 2001-07-31 | 2008-07-23 | 日油株式会社 | Bio-related substance modifier and method for producing polyoxyalkylene derivative |
| US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
-
2007
- 2007-02-27 KR KR1020087023276A patent/KR20090042755A/en not_active Withdrawn
- 2007-02-27 AT AT07751827T patent/ATE475433T1/en not_active IP Right Cessation
- 2007-02-27 CA CA002656693A patent/CA2656693A1/en not_active Abandoned
- 2007-02-27 CN CN2007800070799A patent/CN101500614B/en not_active Expired - Fee Related
- 2007-02-27 DE DE602007008074T patent/DE602007008074D1/en active Active
- 2007-02-27 JP JP2008557339A patent/JP2009528430A/en active Pending
- 2007-02-27 WO PCT/US2007/005094 patent/WO2007100829A2/en not_active Ceased
- 2007-02-27 US US12/280,849 patent/US7816484B2/en not_active Expired - Fee Related
- 2007-02-27 EP EP07751827A patent/EP1996237B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| EP1996237A2 (en) | 2008-12-03 |
| WO2007100829A2 (en) | 2007-09-07 |
| DE602007008074D1 (en) | 2010-09-09 |
| US7816484B2 (en) | 2010-10-19 |
| CN101500614B (en) | 2011-08-10 |
| US20090054621A1 (en) | 2009-02-26 |
| WO2007100829A3 (en) | 2007-11-15 |
| CA2656693A1 (en) | 2007-09-07 |
| CN101500614A (en) | 2009-08-05 |
| JP2009528430A (en) | 2009-08-06 |
| ATE475433T1 (en) | 2010-08-15 |
| KR20090042755A (en) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0824126B2 (en) | Preparation of carboxylic acid-containing polyether and biologically active substances derived thereof | |
| EP1397413B1 (en) | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties | |
| JP5264073B2 (en) | Living radical polymerization initiator containing a functional group capable of reacting with a polypeptide, etc., comb polymer obtained by using the same, polypeptide complex and drug obtained therefrom | |
| US7943141B2 (en) | Activated polyoxazolines and compositions comprising the same | |
| US5686110A (en) | Water soluble complex of an alkyl or olefinic end capped polyalkylene oxide and a water insoluble substance | |
| EP2412744B1 (en) | Method for preparing branched functionalised polymers using branched polyol cores | |
| US7544738B2 (en) | Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol) | |
| CN103492458B (en) | Polyoxyethylene derivatives with multiple hydroxyl groups at the end | |
| US7605257B2 (en) | Processes for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants | |
| JP5017107B2 (en) | Living radical polymerization initiator containing a functional group capable of reacting with a polypeptide, etc., comb polymer obtained by using the same, polypeptide complex and drug obtained therefrom | |
| EP3279236B1 (en) | Biodegradable polyethylene glycol derivative having cyclic benzylidene acetal linker | |
| US7816484B2 (en) | Method for making polyethylene glycol carbonates | |
| Burggraef et al. | Exactly defined molecular weight poly (ethylene glycol) allows for facile identification of PEGylation sites on proteins | |
| WO2009122176A2 (en) | Rapamycin carbonate esters | |
| US8785660B2 (en) | Polyoxyalkylene-modified lipid and method for producing the same | |
| KR100406739B1 (en) | Aqueous-prodrug compound comprising moiety of paclitaxelor derivatives thereof, method of preparing same and pharmaceutical composition comprising same | |
| CA3094055A1 (en) | Branched monodispersed polyethylene glycol, intermediate and methods for producing same | |
| Fricke et al. | Carbonate couplers and functional cyclic carbonates from amino acids and glucosamine | |
| JP3399100B2 (en) | Oxyalkylene derivative | |
| US20040249119A1 (en) | Novel mPEG propionaldehyde precursor | |
| JP3202744B2 (en) | Protein modification reagent containing polyethylene glycol derivative | |
| WO2025176818A1 (en) | Defined molecular weight pegylation agents | |
| KR100551096B1 (en) | Novel Y-polyethylene glycol derivatives and preparation method thereof | |
| EP3604386A1 (en) | Degradable polyethylene glycol derivative having disulfide linker | |
| MX2008008916A (en) | High efficiency method of preparing polyalkylene oxide carboxylic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080926 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DR REDDY'S LABORATORIES (EU) LIMITED |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REF | Corresponds to: |
Ref document number: 602007008074 Country of ref document: DE Date of ref document: 20100909 Kind code of ref document: P |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: VALIPAT / PATENTS.EU S.A. C/O GUINNARD SA |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20100728 |
|
| LTIE | Lt: invalidation of european patent or patent extension |
Effective date: 20100728 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: BK Free format text: ONTERECHT VERVALLEN OP 28.07.2010PUBLIKATIE VERVAL I.E. 24.11.2010I.E. 2010/40 Effective date: 20100728 Ref country code: NL Ref legal event code: T3 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: FIAMMENGHI-FIAMMENGHI |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101129 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101128 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101028 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101029 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20110216 Year of fee payment: 5 Ref country code: DE Payment date: 20110215 Year of fee payment: 5 Ref country code: FR Payment date: 20110217 Year of fee payment: 5 Ref country code: IT Payment date: 20110224 Year of fee payment: 5 Ref country code: CH Payment date: 20110202 Year of fee payment: 5 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20101108 |
|
| 26N | No opposition filed |
Effective date: 20110429 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20110202 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007008074 Country of ref document: DE Effective date: 20110429 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110228 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110227 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20120901 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20120227 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120229 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120229 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20121031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120227 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007008074 Country of ref document: DE Effective date: 20120901 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120227 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20120901 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120229 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20110227 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120901 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20100728 |